Nasal Spray Formulation
On this page
Direct answer
Nasal sprays deliver a metered 50-100 microlitre actuation of solution or suspension to the nasal mucosa, exploited in two directions: locally for allergic rhinitis (fluticasone, mometasone) and systemically for drugs destroyed by the gut and first-pass metabolism — salmon calcitonin, desmopressin, sumatriptan and emergency naloxone — because the vascular mucosa absorbs quickly and bypasses the liver. Formulation follows nasal physiology: the cavity runs near pH 5.5-6.5, so products buffer close to that; tonicity sits near saline to avoid stinging; viscosity agents and mucoadhesives such as hydroxypropyl methylcellulose slow mucociliary clearance; and preservatives, chiefly benzalkonium chloride, serve multidose bottles though chronic use raises ciliotoxicity concerns. Performance lives in the device-formulation pair: spray content uniformity across the bottle's life, droplet size distribution (tens of micrometres, far above inhaler aerosols), spray pattern and plume geometry, plus priming and tail-off.
What you must remember
- Physiological anchors: nasal secretions around pH 5.5-6.5; mucociliary clearance halves mucus turnover in about 15-20 minutes, the window a formulation must beat.
- Dose volume: metered sprays are commonly 50-100 microlitres per actuation — exceeding about 150 microlitres risks run-off and swallowing.
- Route logic: high vascularity plus bypass of hepatic first pass gives rapid onset; molecules below roughly 1,000 daltons with some lipophilicity absorb best; bioavailability still trails injection for most polar drugs.
- Excipient set: buffered aqueous vehicle, NaCl or glycerol for tonicity, celluloses or polyvinylpyrrolidone for viscosity and mucoadhesion, benzalkonium chloride as preservative, chitosan or cyclodextrins as absorption enhancers within ciliotoxicity limits.
- Device tests (pharmacopoeial convention): spray content uniformity through primed life, droplet or particle size by laser diffraction, spray pattern and plume geometry, priming actuations and tail-off characterisation.
- Droplet size window: nasal deposition favours droplets well above 10 micrometres; sub-10 micrometre fractions risk reaching the lungs, distinguishing nasal sprays from inhalers.
- Sterile or not: conventional nasal sprays are not required sterile but carry microbial limits; preservative choice must respect the ciliary beat.
- Indian practice anchors: intranasal naloxone in opioid overdose first-aid programmes and intranasal midazolam for seizure clusters show the emergency niche; fluticasone and mometasone sprays dominate community-pharmacy allergic rhinitis counselling.
From powder to plume
Take a suspension nasal steroid from development to patient. The micronised drug, particles of a few micrometres, disperses in an aqueous vehicle buffered near pH 6 with microcrystalline cellulose as suspending aid, glycerol for tonicity and benzalkonium chloride for the multidose bottle. The pump is a precision part: dipping tube, spring mechanism and a metering chamber delivering, say, 100 microlitres per stroke. Development then characterises the pair — laser diffraction gives a droplet distribution centered in the tens of micrometres, spray-pattern testing onto an impaction plate confirms a repeatable ellipse, and content uniformity is proven at beginning, middle and end of fill, after priming and through the final usable actuations. None of these is a property of the liquid alone, which is why generics must match device performance in vitro rather than simply copy the formulation.
Counselling closes the loop. Prime a new bottle until a fine mist appears, blow the nose gently, aim away from the septum, alternate nostrils, and respect the labelled dose — steroid sprays take days to work. For emergencies the counselling inverts: a naloxone 4 milligram spray goes into a nostril of an unresponsive person while help is summoned, repeatable if breathing does not return. Both extremes depend on the same metered physics, a contrast examiners like drawn explicitly.
How the exam frames nasal delivery
The comparison with pulmonary inhalers is the standard trap: candidates transfer the 1-5 micrometre deposition logic of inhalers to the nose, when nasal sprays deliberately sit above 10 micrometres so the dose stays on the mucosa. Second, the absorption-enhancer question must mention the price — bile salts and surfactants at effective concentrations slow or halt ciliary beating, so chronic products prefer safer polymers like chitosan. Third, "bypasses first-pass metabolism" is claimed too broadly; large polar peptides still achieve modest bioavailability. Finally, priming and tail-off belong to the dosage form: the first sprays of a new or idle bottle are under-dosed until the metering chamber purges, which is why labels instruct priming and why content-uniformity testing spans the bottle's whole life.
Frequently asked questions
Why does the nasal route give rapid systemic absorption?
The mucosa is highly vascular and drains to systemic circulation without passing through the portal vein, so gut acid, enzymatic degradation and hepatic first-pass metabolism are all bypassed.
Which tests characterise a nasal spray product?
Spray content uniformity through the canister's life, droplet size distribution, spray pattern and plume geometry, plus priming and tail-off studies — all testing the device-formulation combination.
What droplet size should a nasal spray produce?
Droplets predominantly larger than about 10 micrometres deposit in the nose; smaller droplets risk inhalation into the lungs, which is the opposite of inhaler aerosol design.
Which drugs are successfully given intranasally?
Steroids and antihistamines locally; systemically, salmon calcitonin, desmopressin, sumatriptan, and emergency naloxone and midazolam — small, potent molecules or drugs needing rapid onset.
Why must absorption enhancers be used cautiously?
Effective enhancers such as surfactants and bile salts can damage nasal cilia at concentrations that improve absorption, so chronic formulations use milder polymers within ciliotoxicity limits.